Abstract:Misfolding- and aggregation-prone proteins underlying Parkinson's, Huntington's and Machado-Joseph diseases, namely alpha-synuclein, huntingtin, and ataxin-3 respectively, adopt numerous intracellular conformations during pathogenesis, including globular intermediates and insoluble amyloid-like fibrils. Such conformational diversity has complicated research into amyloid-associated intracellular dysfunction and neurodegeneration. To this end, recombinant single-chain Fv antibodies (scFvs) are compelling molecular tools that can be selected against specific protein conformations, and expressed inside cells as intrabodies, for investigative and therapeutic purposes.Using atomic force microscopy (AFM) and live-cell fluorescence microscopy, we report that a human scFv selected against the fibrillar form of alpha-synuclein targets isomorphic conformations of misfolded polyglutamine proteins. When expressed in the cytoplasm of striatal cells, this conformation-specific intrabody co-localizes with intracellular aggregates of misfolded ataxin-3 and a pathological fragment of huntingtin, and enhances the aggregation propensity of both disease-linked polyglutamine proteins. Using this intrabody as a tool for modulating the kinetics of amyloidogenesis, we show that escalating aggregate formation of a pathologic huntingtin fragment is not cytoprotective in striatal cells, but rather heightens oxidative stress and cell death as detected by flow cytometry. Instead, cellular protection is achieved by suppressing aggregation using a previously described intrabody that binds to the amyloidogenic N-terminus of huntingtin. Analogous cytotoxic results are observed following conformational targeting of normal or polyglutamine-expanded human ataxin-3, which partially aggregate through non-polyglutamine domains.These findings validate that the rate of aggregation modulates polyglutamine-mediated intracellular dysfunction, and caution that molecules designed to specifically hasten aggregation may be detrimental as therapies for polyglutamine disorders. Moreover, our findings introduce a novel antibody-based tool that, as a consequence of its general specificity for fibrillar conformations and its ability to function intracellularly, offers broad research potential for a variety of human amyloid diseases.

Inhibition of Polyglutamine Misfolding with D-Enantiomeric Peptides Identified by Mirror Image Phage Display Selection

AQAMAN, a bisamidine-based inhibitor of toxic protein inclusions in neurons, ameliorates cytotoxicity in polyglutamine disease models

Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.

In vivo suppression of polyglutamine aggregation via co-condensation of the molecular chaperone DNAJB6

A Brain-Targeting Lipidated Peptide for Neutralizing RNA-mediated Toxicity in Polyglutamine Diseases

Expanded Polyglutamine-Binding Peptoid As a Novel Therapeutic Agent for Treatment of Huntington's Disease.

Polyglutamine expansion induced dynamic misfolding of Androgen Receptor

Single Homopolypeptide Chains Collapse Into Mechanically Rigid Conformations

Conformation Polymorphism of Polyglutamine Proteins

Length-Dependent Structural Transformations of Huntingtin PolyQ Domain Upon Binding to 2D-Nanomaterials

Pharmacological Induction of Heat-Shock Proteins Alleviates Polyglutamine-Mediated Motor Neuron Disease.

Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity

Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein

Proteins in Aggregates Functionally Impact Multiple Neurodegenerative Disease Models by Forming Proteasome-Blocking Complexes

Inhibitor-based modulation of huntingtin aggregation mechanisms reduces fibril toxicity

Photocontrol of the β-Hairpin Polypeptide Structure through an Optimized Azobenzene-Based Amino Acid Analogue

Proline/arginine dipeptide repeat polymers derail protein folding in amyotrophic lateral sclerosis

The Expanding Clinical Universe of Polyglutamine Disease.

Alleviating Neurodegeneration in Drosophila Models of PolyQ Diseases

Solubilization and disaggregation of polyglutamine peptides

Structure prediction of polyglutamine disease proteins: comparison of methods